Considering that the clinicopathological parameters may affect the distribution of PBL subsets, we analyzed the correlations of PBL subsets with clinicopathological parameters, such as Ki-67, Karnofsky Performance Status (KPS), menstrual status, age, BRCA status, advanced treatment line, type of treatment, neoadjuvant/adjuvant therapy use, metastasis location and status, tumor size, lymph node metastasis status, and clinical stage. This evidence concerns the gene MKI67 and neoplasm.